PTPRC and leukemia: During disease progression, PB leukemia cells (GFP+B220+) were monitored on days 14, 17, 21, 25 and 28 post BMT, which revealed a significantly higher leukemia cell total and percentage in the Rora deficiency group recipients (Figure 6B and C).